Literature DB >> 32894646

Expeditious Total Synthesis of Hemiasterlin through a Convergent Multicomponent Strategy and Its Use in Targeted Cancer Therapeutics.

Jiraborrirak Charoenpattarapreeda1, Stephen J Walsh1,2, Jason S Carroll2, David R Spring1.   

Abstract

Hemiasterlin is an antimitotic marine natural product with reported sub-nanomolar potency against several cancer cell lines. Herein, we describe an expeditious total synthesis of hemiasterlin featuring a four-component Ugi reaction (Ugi-4CR) as the key step. The convergent synthetic strategy enabled rapid access to taltobulin (HTI-286), a similarly potent synthetic analogue. This short synthetic sequence enabled investigation of both hemiasterlin and taltobulin as cytotoxic payloads in antibody-drug conjugates (ADCs). These novel ADCs displayed sub-nanomolar cytotoxicity against HER2-expressing cancer cells, while showing no activity against antigen-negative cells. This study demonstrates an improved synthetic route to a highly valuable natural product, facilitating further investigation of hemiasterlin and its analogues as potential payloads in targeted therapeutics.
© 2020 The Authors. Published by Wiley-VCH GmbH.

Entities:  

Keywords:  antibody-drug conjugates; hemiasterlin; multicomponent reactions; targeted therapeutics; total synthesis

Year:  2020        PMID: 32894646      PMCID: PMC7756509          DOI: 10.1002/anie.202010090

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  37 in total

1.  Synthesis and biological activity of analogues of the antimicrotubule agent N,beta,beta-trimethyl-L-phenylalanyl-N(1)-[(1S,2E)-3-carboxy-1-isopropylbut-2-enyl]- N(1),3-dimethyl-L-valinamide (HTI-286).

Authors:  Arie Zask; Gary Birnberg; Katherine Cheung; Joshua Kaplan; Chuan Niu; Emily Norton; Ronald Suayan; Ayako Yamashita; Derek Cole; Zhilian Tang; Girija Krishnamurthy; Robert Williamson; Gulnaz Khafizova; Sylvia Musto; Richard Hernandez; Tami Annable; Xiaoran Yang; Carolyn Discafani; Carl Beyer; Lee M Greenberger; Frank Loganzo; Semiramis Ayral-Kaloustian
Journal:  J Med Chem       Date:  2004-09-09       Impact factor: 7.446

2.  Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability.

Authors:  Marianne S Poruchynsky; Jong-Hyeok Kim; Eva Nogales; Tami Annable; Frank Loganzo; Lee M Greenberger; Dan L Sackett; Tito Fojo
Journal:  Biochemistry       Date:  2004-11-09       Impact factor: 3.162

Review 3.  Natural product synthesis using multicomponent reaction strategies.

Authors:  Barry B Touré; Dennis G Hall
Journal:  Chem Rev       Date:  2009-09       Impact factor: 60.622

Review 4.  The Catalytic Enantioselective Ugi Four-Component Reactions.

Authors:  Shabnam Shaabani; Alexander Dömling
Journal:  Angew Chem Int Ed Engl       Date:  2018-11-15       Impact factor: 15.336

Review 5.  Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes.

Authors:  Meghdad Abdollahpour-Alitappeh; Majid Lotfinia; Tohid Gharibi; Jalal Mardaneh; Behrouz Farhadihosseinabadi; Pegah Larki; Babak Faghfourian; Koushan Sineh Sepehr; Kazem Abbaszadeh-Goudarzi; Ghasem Abbaszadeh-Goudarzi; Behrooz Johari; Mohammad Reza Zali; Nader Bagheri
Journal:  J Cell Physiol       Date:  2018-11-27       Impact factor: 6.384

6.  Total Synthesis of the Marine Natural Product Hemiasterlin by Organocatalyzed α-Hydrazination.

Authors:  Jan Hendrik Lang; Peter G Jones; Thomas Lindel
Journal:  Chemistry       Date:  2017-08-16       Impact factor: 5.236

7.  Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer.

Authors:  John M Lambert; Ravi V J Chari
Journal:  J Med Chem       Date:  2014-07-10       Impact factor: 7.446

8.  DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.

Authors:  Yusuke Ogitani; Tetsuo Aida; Katsunobu Hagihara; Junko Yamaguchi; Chiaki Ishii; Naoya Harada; Masako Soma; Hiromi Okamoto; Masataka Oitate; Shingo Arakawa; Takehiro Hirai; Ryo Atsumi; Takashi Nakada; Ichiro Hayakawa; Yuki Abe; Toshinori Agatsuma
Journal:  Clin Cancer Res       Date:  2016-03-29       Impact factor: 12.531

9.  Structural Insights into the Pharmacophore of Vinca Domain Inhibitors of Microtubules.

Authors:  Yuxi Wang; Frederick W Benz; Yangping Wu; Qisheng Wang; Yunfeng Chen; Xiangzheng Chen; Huiyan Li; Yonghui Zhang; Rundong Zhang; Jinliang Yang
Journal:  Mol Pharmacol       Date:  2015-12-09       Impact factor: 4.436

Review 10.  Antibodies to watch in 2020.

Authors:  Hélène Kaplon; Mrinalini Muralidharan; Zita Schneider; Janice M Reichert
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

View more
  4 in total

1.  All-in-one disulfide bridging enables the generation of antibody conjugates with modular cargo loading.

Authors:  Friederike M Dannheim; Stephen J Walsh; Carolina T Orozco; Anders Højgaard Hansen; Jonathan D Bargh; Sophie E Jackson; Nicholas J Bond; Jeremy S Parker; Jason S Carroll; David R Spring
Journal:  Chem Sci       Date:  2022-07-20       Impact factor: 9.969

2.  Rapid and robust cysteine bioconjugation with vinylheteroarenes.

Authors:  Hikaru Seki; Stephen J Walsh; Jonathan D Bargh; Jeremy S Parker; Jason Carroll; David R Spring
Journal:  Chem Sci       Date:  2021-06-07       Impact factor: 9.825

3.  Expeditious Total Synthesis of Hemiasterlin through a Convergent Multicomponent Strategy and Its Use in Targeted Cancer Therapeutics.

Authors:  Jiraborrirak Charoenpattarapreeda; Stephen J Walsh; Jason S Carroll; David R Spring
Journal:  Angew Chem Int Ed Engl       Date:  2020-10-12       Impact factor: 15.336

4.  Divinylpyrimidine reagents generate antibody-drug conjugates with excellent in vivo efficacy and tolerability.

Authors:  Stephen J Walsh; Soleilmane Omarjee; Friederike M Dannheim; Dominique-Laurent Couturier; Dorentina Bexheti; Lee Mendil; Gemma Cronshaw; Toby Fewster; Charlotte Gregg; Cara Brodie; Jodi L Miller; Richard Houghton; Jason S Carroll; David R Spring
Journal:  Chem Commun (Camb)       Date:  2022-02-08       Impact factor: 6.065

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.